Noxopharm Ltd has released a press release.
DARRT-1 study advancing on basis of positive clinical data
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- NOX announces Positive Data from CEP-1 Study of Veyonda
- NOX to Present Clinical Data at COSA Annual Meeting
- Appendix 4C - quarterly
- Change of Registry Address: Automic P/L - Sydney Office
- NOX Subsidiary Announces Important Drug Discovery
Later from Noxopharm
- NOX Receives $3.26M Federal Govt R&D Rebate
- Principal Investigator Discusses LuPIN-1 Study
- Veyonda and Radiotherapy Delivers Clinical Benefits
- FNN interview with Nox Chief Medical Officer on Interim Data
- Noxopharm to expedite Veyonda Clinical Program
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm